Figures computed from official regulatory filings — .
Analysttarget 2 USD (+1999900%) · consensus 4/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 0% · institutions 11.44% · short 6.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Aridis Pharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
8 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Truong Vu | Buy | $50K | conv 68First in 12mo |
| SEC |
| Windham-Bannister Susan Richards | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Patzer Eric | Buy | $50K | conv 78First in 12mo | SEC |
| HAMILTON JOHN F | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jafri Hasan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jafri Hasan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Truong Vu | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Windham-Bannister Susan Richards | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Patzer Eric | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| HAMILTON JOHN F | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| KURLAND FRED | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| KURLAND FRED | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Patzer Eric | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Windham-Bannister Susan Richards | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Jafri Hasan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Windham-Bannister Susan Richards | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Truong Vu | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| KURLAND FRED | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Truong Vu | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Jafri Hasan | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| HAMILTON JOHN F | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Windham-Bannister Susan Richards | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Patzer Eric | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jafri Hasan | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Truong Vu | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |